Clinically low-/intermediate-risk GIST patients with PTEN low expression/PTEN loss may benefit from intensive surveillance, whereas clinically high-risk GIST patients with PTEN low expression/PTEN loss may benefit from further clinical trials to investigate the additional value of mTOR inhibitors to standard adjuvant TKIs. The gene discussed is MTOR; the disease is gastrointestinal stromal tumor.